Coagulation abnormalities and thrombosis in patients with COVID-19.
作者信息
Levi Marcel, Thachil Jecko, Iba Toshiaki, Levy Jerrold H
机构信息
Cardiometabolic Programme, National Institute for Health Research University College London Hospitals (UCLH) Biomedical Research Centre, London, UK; Department of Medicine, UCLH National Health Service Foundation Trust, London, NW1 2PG, UK.
Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
出版信息
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
Abstract
摘要
相似文献
1
Coagulation abnormalities and thrombosis in patients with COVID-19.新型冠状病毒肺炎患者的凝血异常与血栓形成
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
2
COVID-19 coagulopathy: an evolving story.新冠病毒感染相关凝血功能障碍：一个不断演变的故事。
Lancet Haematol. 2020 Jun;7(6):e425. doi: 10.1016/S2352-3026(20)30151-4.
3
COVID-19 and SIC (!).2019冠状病毒病与噬血细胞性淋巴组织细胞增生症（！）
J Vasc Surg. 2020 Sep;72(3):1148-1150. doi: 10.1016/j.jvs.2020.05.047. Epub 2020 Jun 1.
4
Hemostasis profile in COVID-19 infection.新型冠状病毒肺炎感染中的止血情况
Rev Assoc Med Bras (1992). 2020 May;66(5):571-572. doi: 10.1590/1806-9282.66.5.571. Epub 2020 Jul 3.
5
SARS-CoV-2: What is known and what there is to know-Focus on coagulation and lipids.严重急性呼吸综合征冠状病毒2：已知与未知——聚焦凝血与脂质
Eur J Clin Invest. 2020 Jul;50(7):e13311. doi: 10.1111/eci.13311. Epub 2020 Jun 25.
6
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
7
COVID-19 coagulopathy vs disseminated intravascular coagulation.新型冠状病毒肺炎凝血病与弥散性血管内凝血
Blood Adv. 2020 Jun 23;4(12):2850. doi: 10.1182/bloodadvances.2020002197.
8
Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both.2019冠状病毒病凝血障碍：弥散性血管内凝血和血栓性微血管病——是其一、均不是或两者皆是。
Semin Thromb Hemost. 2020 Oct;46(7):781-784. doi: 10.1055/s-0040-1712156. Epub 2020 Jun 8.
9
Prevention and treatment of COVID-19-associated hypercoagulability: Recommendations of the Algerian society of transfusion and hemobiology.新型冠状病毒肺炎相关高凝状态的预防与治疗：阿尔及利亚输血与血液生物学学会的建议
Transfus Clin Biol. 2020 Nov;27(4):203-206. doi: 10.1016/j.tracli.2020.09.004. Epub 2020 Oct 3.
10
COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).新型冠状病毒肺炎与止血：来自意大利血栓形成与止血协会（SISET）的立场文件。
Blood Transfus. 2020 May;18(3):167-169. doi: 10.2450/2020.0083-20. Epub 2020 Apr 8.
引用本文的文献
1
Multisystem Endothelial Inflammation: A Key Driver of Adverse Events Following mRNA-Containing COVID-19 Vaccines.多系统内皮炎症：含mRNA的新冠疫苗接种后不良事件的关键驱动因素
Vaccines (Basel). 2025 Aug 12;13(8):855. doi: 10.3390/vaccines13080855.
2
Dynamic changes of Ct values of N gene and ORF1ab genes and laboratory parameters in patients with COVID-19 caused by SARS-CoV-2 B.1, BA.2, and BA.5 variants and their correlation with clinical characteristics.由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）B.1、BA.2和BA.5变异株引起的新型冠状病毒肺炎（COVID-19）患者中N基因和ORF1ab基因的Ct值动态变化及实验室参数及其与临床特征的相关性
Front Microbiol. 2025 Aug 5;16:1606306. doi: 10.3389/fmicb.2025.1606306. eCollection 2025.
3
Blood component utilization in hospitalized COVID-19 patients: Experience from a dedicated COVID-19 center.住院COVID-19患者的血液成分使用情况：来自一家专门的COVID-19中心的经验。
Asian J Transfus Sci. 2025 Jan-Jun;19(1):108-113. doi: 10.4103/ajts.ajts_179_21. Epub 2022 Dec 12.
4
COVID-19: a vascular nightmare unfolding.新冠病毒肺炎：一场正在展现的血管噩梦。
Front Immunol. 2025 Aug 1;16:1593885. doi: 10.3389/fimmu.2025.1593885. eCollection 2025.
5
Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.波纳替尼而非新型Abl激酶抑制剂阿西替尼可激活血小板、白细胞和内皮细胞的肿瘤坏死因子信号通路，从而引发动脉粥样硬化斑块炎症、心肌梗死和中风。
Circulation. 2025 Aug 5. doi: 10.1161/CIRCULATIONAHA.125.073610.
6
COVID-19 infection increases the risk of venous thromboembolism during pregnancy and the postpartum period.新冠病毒感染会增加孕期和产后静脉血栓栓塞的风险。
Eur J Epidemiol. 2025 Jul 11. doi: 10.1007/s10654-025-01268-z.
7
Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia.脂蛋白(a)对慢性肢体威胁性缺血的糖尿病患者下肢血管重建术后心血管事件的预后价值。
Cardiovasc Diabetol. 2025 Jul 10;24(1):271. doi: 10.1186/s12933-025-02833-2.
8
Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant.新型冠状病毒肺炎的病理生理学：缓激肽拮抗剂依卡替班ICAT-COVID临床试验的事后分析
Pathogens. 2025 May 27;14(6):533. doi: 10.3390/pathogens14060533.
9
The association between prolonged lymphopenia and in-hospital venous thromboembolism among different respiratory virus infections: a retrospective cohort study.不同呼吸道病毒感染中持续性淋巴细胞减少与院内静脉血栓栓塞之间的关联：一项回顾性队列研究。
Res Pract Thromb Haemost. 2025 Apr 24;9(3):102868. doi: 10.1016/j.rpth.2025.102868. eCollection 2025 Mar.
10
Time series differences in coagulopathy in mechanically ventilated COVID-19 and bacterial pneumonia patients: a nationwide observational study in Japan.机械通气的新冠肺炎患者与细菌性肺炎患者凝血功能障碍的时间序列差异：日本一项全国性观察研究
Thromb J. 2025 Jun 10;23(1):61. doi: 10.1186/s12959-025-00747-3.
本文引用的文献
1
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.国际血栓与止血学会（ISTH）关于新冠病毒病（COVID-19）凝血病识别与管理的临时指南。
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
2
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
3
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.西雅图地区危重症新冠患者-病例系列。
N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
4
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
How I treat disseminated intravascular coagulation.如何治疗弥散性血管内凝血。
Blood. 2018 Feb 22;131(8):845-854. doi: 10.1182/blood-2017-10-804096. Epub 2017 Dec 18.
Zotero 插件